Henlius Brings In Abbott As Another Partner In Brazil
Local Player Eurofarma Had Recently Struck A $50.5m Deal
Chinese player Shanghai Henlius Biotech has out licensed semi-exclusive rights to some of its biosimilars in Brazil again, shortly after signing a major deal covering 16 Latin American countries.
You may also be interested in...
Shanghai Henlius Biotech has celebrated an Australian approval for its Hanquyou trastuzumab biosimilar rival to Herceptin, which has been approved by the country’s TGA under the names Tuzucip and Trastucip via local partner Cipla.
Henlius has administered the first dose in its international Phase III trial into its denosumab biosimilar candidate, HLX14. The firm has also revealed that its new Songjiang plant has been granted GMP equivalence with EU practices.
Organon has agreed to pay an upfront price of $73m plus potentially a further $30m in milestone payments this year alone for the rights to Shanghai Henlius Biotech’s HLX14 denosumab and HLX11 pertuzumab biosimilar candidates outside China. The deal also offers Organon an option to negotiate with Henlius for rights to its ipilimumab biosimilar.